Wrinkle Removal Meditoxin Type A Botulinum Toxin Injections 100units

Description

It appears as a lyophilized white powder for injection in a colorless
transparent vial.

Indication and Usage

1. Meditoxin is indicated for the treatment of benign essential
blepharospasm in patients 18 years of age and older.

2. Temporary improvement of serious glabellar wrinkles ranging from
moderate to severe associated with corrugators muscle and/or procerus
muscle activities in adults over the age of 18 and below the age of 65.

3. Muscle spasticity : Meditoxin is indicated for the treatment of upper limb
spasticity associated with stroke in patient 20 years of age and older.

Dosage and Administration

1. Blepharospasm For blepharospasm, reconstituted Meditoxin
(see Dilution Table) is injected
using a sterile, 27 - 30 gauge needle without electromyographic guidance.
The initial recommended dose is 1.25 - 2.5 U (0.05 mL to 0.1 mL volume at
each site) injected into the medial and lateral pre-tarsal orbicularis oculi of
the upper lid and into the lateral pre-tarsal orbicularis oculi of the lower lid.
In general, the initial effect of the injections is seen within three days and
reaches a peak at one to two weeks post-treatment. Each treatment lasts
approximately three months, following which the procedure can be repeated.
At repeat treatment sessions, the dose may be increased up to two-fold
if the response from the initial treatment is considered insufficient-usually
defined as an effect that does not last longer than two months. However
there appears to be little benefit obtainable from injecting more than 5.0
U per site. Some tolerance may be found when the drug is used in treating
blepharospasm if treatments are given any more frequently than every three
months, and is rare to have the effect be permanent.
The cumulative dose of Meditoxin
treatment in a 30-day period should not
exceed 200 U.

2. Glabellar Wrinkles
Meditoxin is reconstituted to make 100U/2.5mL (4U/0.1 mL) with 0.9%
non-preserved sterile saline. Using a 30 gauge needle, 20U of Meditoxin
is injected to two places on the corrugators muscle for each eye and one place

on the procerus muscle, total of 5 sites with 0.1 mL per site. To reduce complications

of drooping (ptosis) eyelids, injection is avoided in the levator palpebrae superioris vicinity,
especially for patients with large corrugators muscles. When administering
injection in the medial end of corrugators muscle and in the midpoint
between each eyebrow, it must be done in a place at least 1 cm apart from
supraorbital ridge. Meditoxin is injected with caution so that it does not
enter the blood vessel, and to prevent effusion from the area below the
orbital ridge, firmly place a thumb or an index finger on the area below the
orbital ridge prior to injection. During injection, the needle should point
upward toward the center and injection dose must be measured accurately.
The corrugators muscle and orbicularis oculi muscle move the center of the
forehead and generate the glabellar facial wrinkles. The procerus muscle and
depressor supercilii muscle pull the forehead down. Frowning or glabellar
wrinkles are produced by thesemuscles. Because the position, size, and use
of these muscles are different for individuals, an effective dose is determined
based on general observations on the patient’s ability to move the injected
superficial muscles. The treatment effect of Meditoxin for glabellar

Dilution technique

Prior to injection, reconstitute freeze-dried Meditoxin
with sterile normal saline without a preservative. 0.9% Sodium chloride Injection is the
recommended diluent. Draw up the proper amount of diluent in the
appropriate size syringe. The diluent should be injected gently into the vial.
Discard the vial if a vacuum does not pull the diluent into the vial. Gently
mix Meditoxin with the saline by rotating the vial. Meditoxin
should be administered within 24 hours after reconstitution. During this time
period, reconstituted Meditoxin should be stored in a refrigerator(2 - 8℃).
Reconstituted Meditoxin should be clear, colorless and free of particulate
matter. Parenteral drug products should be inspected visually for particulate
matter and discoloration prior to administration. Because the drug and
diluent do not contain any preservative, one vial of Meditoxin
should be used for a single patient.